Literature DB >> 2550044

In vivo microscopy of the liver after injection of Lipiodol into the hepatic artery and portal vein in the rat.

Z Kan1, K Ivancev, I Hägerstrand, V P Chuang, A Lunderquist.   

Abstract

The route, distribution and clearance of intraarterially administered Lipiodol in the liver has been the subject of much speculation. The hepatic microcirculation was therefore studied by in vivo microscopy after injection of Lipiodol into the hepatic artery and the portal vein in rats. After intraarterial injection, Lipiodol rapidly entered the portal branches through arterio-portal communications. Lipiodol also passed through the sinusoids from the portal into the hepatic veins and then into the systemic circulation. Sinusoidal congestion occurred when the oil droplets filled the liver microcirculation and resolved as the oil was cleared. It is of clinical significance to note the passage of the oil into the systemic circulation after arterial injection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550044

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  19 in total

1.  A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial.

Authors:  Takahiro Yamasaki; Satoe Hamabe; Issei Saeki; Yohei Harima; Yuhki Yamaguchi; Koichi Uchida; Shuji Terai; Isao Sakaida
Journal:  J Gastroenterol       Date:  2010-08-25       Impact factor: 7.527

2.  Scanning electron microscopy of intrahepatic microvasculature casts following experimental hepatic artery embolization.

Authors:  H Demachi; O Matsui; T Takashima
Journal:  Cardiovasc Intervent Radiol       Date:  1991 May-Jun       Impact factor: 2.740

3.  Liver anatomy: microcirculation of the liver.

Authors:  Zuxing Kan; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

4.  Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization.

Authors:  Kostas Delaunay; Julien Edeline; Yan Rolland; Nicolas Lepareur; Sophie Laffont; Xavier Palard; Christelle Bouvry; Samuel Le Sourd; Marc Pracht; Valérie Ardisson; Nicolas Noiret; Éric Bellissant; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-04       Impact factor: 9.236

5.  Liver microcirculation after hepatic artery embolization with degradable starch microspheres in vivo.

Authors:  Jian Wang; Satoru Murata; Tatsuo Kumazaki
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

6.  Segmental transcatheter arterial embolization for primary hepatocellular carcinoma.

Authors:  Li Li; Pei-Hong Wu; Jin-Qing Li; Wei-Zhang Zhang; Hao-Gao Lin; Ya-Qi Zhang
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

7.  Hepatic perfusion and hemodynamic effects of transjugular intrahepatic portosystemic shunts.

Authors:  Eric M Walser; Michael Nguyen
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

8.  Biodistribution of rhenium-188 Lipiodol infused via the hepatic artery of rats with hepatic tumours.

Authors:  S J Wang; W Y Lin; M N Chen; B T Hsieh; L H Shen; Z T Tsai; G Ting; F F Knapp
Journal:  Eur J Nucl Med       Date:  1996-01

9.  Selective induction hyperthermia following transcatheter arterial embolization with a mixture of nano-sized magnetic particles (ferucarbotran) and embolic materials: feasibility study in rabbits.

Authors:  Shigeyuki Takamatsu; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Miho Okuda; Takahiro Ougi; Yoshio Ikehata; Isamu Nagano; Hideo Nagae
Journal:  Radiat Med       Date:  2008-05-29

10.  Effective cases of transcatheter arterioportal chemoembolization with high-dose iodized oil for hepatocellular carcinoma.

Authors:  H Oi; T Kim; H Kishimoto; M Matsushita; H Tateishi; J Okamura
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.